
Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and Forecast, 2021-2031
Description
Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and Forecast, 2021-2031
Market Report Coverage - Precision Cardiology
Market Segmentation
ARUP Laboratories, CENTOGENE N.V., Eurofins Scientific, Exact Sciences Corporation, Fulgent Genetics, Inc., Illumina, Inc., Invitae Corporation, Konica Minolta, Inc., Laboratory Corporation of America Holdings, OPKO Health, Inc., OraSure Technologies, Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Sema4 OpCo, Inc., Thermo Fisher Scientific Inc., GENinCode, Devyser Diagnostics AB
Key Questions Answered in this Report:
Our healthcare experts have found the precision cardiology industry to be one of the most rapidly evolving and dynamic markets and the global market for precision cardiology is predicted to grow at a CAGR of 12.90% over the forecast period of 2021-2031. The market is driven by certain factors, which includes the rising burden of cardiovascular diseases, increasing focus on early cardiovascular disease screening, and decreasing cost of sequencing.
Currently, the precision cardiology industry is witnessing an upsurge due to the rising burden of cardiovascular diseases, increasing focus on early cardiovascular disease screening, and decreasing cost of sequencing. Furthermore, companies are focusing on the development of precision cardiology tests based on advanced sequencing technologies, which is expected to further support physicians to offer better informed clinical decisions in the field of cardiovascular care. The development of advanced precision cardiology tests also enables the research community to establish effective strategies for the discovery of novel genetic biomarkers associated with cardiovascular diseases, which could be harnessed to develop novel therapies.
Within the research report, the market is segmented on the basis of service, sample, technology, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the incidence associated with cardiovascular diseases, worldwide has created a buzz among the biotechnology companies to further invest in the development of precision cardiology tests based on sequencing technologies for supporting physicians to offer precision care in the field of cardiology. Due to the expansive service portfolio and massive geographical presence, Laboratory Corporation of America Holdings has been the leading player in the precision cardiology ecosystem.
On the basis of region, North America holds the largest share of the precision cardiology market due to the presence of market leaders such as Laboratory Corporation of America Holdings, Illumina, Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Incorporated in the U.S. coupled with the significant adoption of high-fidelity precision cardiology tests for diagnosing cardiovascular diseases. Further, rising fund infusions by the federal organizations coupled with increasing investments for precision cardiology test development, are some of the prominent underlying factors supporting the growth of the North America precision cardiology market. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2021-2031. This is majorly attributed to the underlying factors such as the rising incidence of cardiovascular diseases, increase in healthcare awareness, steady economy leading to higher focus on research, and growing adoption of precision cardiology tests, among others.
*PDF email from publisher allows for 1-3 users, with permission to print*
Market Report Coverage - Precision Cardiology
Market Segmentation
- Offering - Product and Service
- Sample - Blood and Non-Blood
- Technology - Sequencing, Polymerase Chain Reaction (PCR), Microarray, and Other Technologies
- Application - Cardiomyopathy, Arrhythmia, Aortopathy and Vascular Diseases, Familial Hypercholesterolemia (FH), Congenital Heart Defects and Syndromes, and Other Applications
- End User - Hospitals and Diagnostic Laboratories, Academic and Research Institutes, and Other End Users
- North America - U.S., and Canada
- Europe - Germany, France, U.K., Italy, Spain, Switzerland, and Rest-of-Europe
- Asia-Pacific - China, India, Japan, South Korea, Australia, and Rest-of-Asia-Pacific
- Latin America - Brazil, Mexico, and Rest-of-Latin America
- Rest-of-the-World
- Rising Burden of Cardiovascular Diseases
- Increasing Focus on Early Cardiovascular Disease (CVD) Screening
- Decreasing Cost of Sequencing
- Lack of Established Regulatory Policies in the Precision Cardiology Ecosystem
- Lack of High Complexity Testing Centers
- Existing Diagnostic Confidence on Conventional Cardiovascular Disease (CVD) Tests
- Massive Scope for Adoption of NGS-Based Cardiology Tests in Emerging Markets
ARUP Laboratories, CENTOGENE N.V., Eurofins Scientific, Exact Sciences Corporation, Fulgent Genetics, Inc., Illumina, Inc., Invitae Corporation, Konica Minolta, Inc., Laboratory Corporation of America Holdings, OPKO Health, Inc., OraSure Technologies, Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Sema4 OpCo, Inc., Thermo Fisher Scientific Inc., GENinCode, Devyser Diagnostics AB
Key Questions Answered in this Report:
- How is precision cardiology revolutionizing the field of cardiovascular care?
- What are the major market drivers, challenges, and opportunities in the global precision cardiology market?
- What are the underlying structures resulting in the emerging trends within the global precision cardiology market?
- How did the COVID-19 pandemic impact the global precision cardiology ecosystem?
- What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
- What are the key regulatory implications in developed and developing regions pertaining to the use of precision cardiology products and services?
- What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
- How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
- Offering (product and service)
- Sample (blood and non-blood)
- Technology (sequencing, polymerase chain reaction, microarray, and other technologies)
- Application (cardiomyopathy, arrhythmia, aortopathy and vascular diseases, familial hypercholesterolemia, congenital heart defects and syndromes, and other applications)
- End user (hospitals and diagnostic laboratories, academic and research institutes, and other end users)
- Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
- What are the growth opportunities for the companies in the region of their operation?
- Who are the leading players with significant offerings in the global precision cardiology market?
- Which companies are anticipated to be highly disruptive in the future, and why?
Our healthcare experts have found the precision cardiology industry to be one of the most rapidly evolving and dynamic markets and the global market for precision cardiology is predicted to grow at a CAGR of 12.90% over the forecast period of 2021-2031. The market is driven by certain factors, which includes the rising burden of cardiovascular diseases, increasing focus on early cardiovascular disease screening, and decreasing cost of sequencing.
Currently, the precision cardiology industry is witnessing an upsurge due to the rising burden of cardiovascular diseases, increasing focus on early cardiovascular disease screening, and decreasing cost of sequencing. Furthermore, companies are focusing on the development of precision cardiology tests based on advanced sequencing technologies, which is expected to further support physicians to offer better informed clinical decisions in the field of cardiovascular care. The development of advanced precision cardiology tests also enables the research community to establish effective strategies for the discovery of novel genetic biomarkers associated with cardiovascular diseases, which could be harnessed to develop novel therapies.
Within the research report, the market is segmented on the basis of service, sample, technology, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the incidence associated with cardiovascular diseases, worldwide has created a buzz among the biotechnology companies to further invest in the development of precision cardiology tests based on sequencing technologies for supporting physicians to offer precision care in the field of cardiology. Due to the expansive service portfolio and massive geographical presence, Laboratory Corporation of America Holdings has been the leading player in the precision cardiology ecosystem.
On the basis of region, North America holds the largest share of the precision cardiology market due to the presence of market leaders such as Laboratory Corporation of America Holdings, Illumina, Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Incorporated in the U.S. coupled with the significant adoption of high-fidelity precision cardiology tests for diagnosing cardiovascular diseases. Further, rising fund infusions by the federal organizations coupled with increasing investments for precision cardiology test development, are some of the prominent underlying factors supporting the growth of the North America precision cardiology market. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2021-2031. This is majorly attributed to the underlying factors such as the rising incidence of cardiovascular diseases, increase in healthcare awareness, steady economy leading to higher focus on research, and growing adoption of precision cardiology tests, among others.
*PDF email from publisher allows for 1-3 users, with permission to print*
Companies Mentioned
ARUP Laboratories
CENTOGENE N.V.
Eurofins Scientific
Exact Sciences Corporation
Fulgent Genetics, Inc.
Illumina, Inc.
Invitae Corporation
Konica Minolta, Inc.
Laboratory Corporation of America Holdings
OPKO Health, Inc.
OraSure Technologies, Inc.
PerkinElmer Inc.
Quest Diagnostics Incorporated
Sema4 OpCo, Inc.
Thermo Fisher Scientific Inc.
GENinCode
Devyser Diagnostics AB
ARUP Laboratories
CENTOGENE N.V.
Eurofins Scientific
Exact Sciences Corporation
Fulgent Genetics, Inc.
Illumina, Inc.
Invitae Corporation
Konica Minolta, Inc.
Laboratory Corporation of America Holdings
OPKO Health, Inc.
OraSure Technologies, Inc.
PerkinElmer Inc.
Quest Diagnostics Incorporated
Sema4 OpCo, Inc.
Thermo Fisher Scientific Inc.
GENinCode
Devyser Diagnostics AB
Table of Contents
242 Pages
- 1 Market
- 1.1 Product Definition
- 1.1.1 Inclusion and Exclusion
- 1.2 Market Scope
- 1.2.1 Key Questions Answered in the Report
- 1.3 Research Methodology
- 1.3.1 Global Precision Cardiology Market: Research Methodology
- 1.3.2 Data Sources
- 1.3.2.1 Primary Data Sources
- 1.3.2.2 Secondary Data Sources
- 1.3.3 Market Estimation Model
- 1.3.4 Criteria for Company Profiling
- 1.4 Market Overview
- 1.4.1 Market Definition
- 1.4.2 Market Footprint and Growth Potential, $Million, 2020-2031
- 1.4.3 Future Potential
- 1.4.4 Impact of COVID-19 on the Global Precision Cardiology Market
- 2 Competitive Landscape
- 2.1 Overview
- 2.2 Synergistic Activities
- 2.3 Product Launches
- 2.4 Product Approvals
- 2.5 Business Expansion
- 2.6 Market Share Analysis, 2019-2020
- 2.7 Growth-Share Analysis
- 2.7.1 Growth-Share Analysis (by Company)
- 2.7.2 Growth-Share Analysis (by Technology)
- 2.7.3 Growth-Share Analysis (by Application)
- 3 Industry Analysis
- 3.1 Overview
- 3.2 Legal Requirements and Framework in the U.S.
- 3.2.1 FDA Regulation
- 3.2.2 CMS Regulation
- 3.3 Legal Requirements and Framework in Europe
- 3.4 Legal Requirements and Framework in Asia-Pacific
- 3.4.1 China
- 3.4.2 Japan
- 3.4.3 South Korea
- 3.4.4 Australia
- 4 Market Dynamics
- 4.1 Overview
- 4.2 Iceberg Analysis of the Global Precision Cardiology Market
- 4.3 Impact Analysis
- 4.4 Market Drivers
- 4.4.1 Rising Burden of Cardiovascular Diseases
- 4.4.2 Increasing Focus on Early Cardiovascular Disease (CVD) Screening
- 4.4.3 Decreasing Cost of Sequencing
- 4.5 Market Restraints
- 4.5.1 Lack of Established Regulatory Policies in the Precision Cardiology Ecosystem
- 4.5.2 Lack of High Complexity Testing Centers
- 4.5.3 Existing Diagnostic Confidence on Conventional Cardiovascular Disease (CVD) Tests
- 4.6 Market Opportunities
- 4.6.1 Massive Scope for Adoption of NGS-Based Cardiology Tests in Emerging Markets
- 5 Global Precision Cardiology Market, by Offering, $Million, 2020 - 2031
- 5.1 Overview
- 5.2 Service
- 5.3 Product
- 6 Global Precision Cardiology Market, by Sample, $Million, 2020 - 2031
- 6.1 Overview
- 6.2 Blood
- 6.3 Non-Blood
- 6.3.1 Saliva
- 6.3.2 Buccal Swabs
- 6.3.3 Other Non-Blood Samples
- 7 Global Precision Cardiology Market, by Technology, $Million, 2020 – 2031
- 7.1 Overview
- 7.2 Sequencing
- 7.2.1 Next-Generation Sequencing (NGS)
- 7.2.2 Sanger Sequencing
- 7.3 Polymerase Chain Reaction (PCR)
- 7.4 Microarray
- 7.5 Other Technologies
- 8 Global Precision Cardiology Market, by Application, $Million, 2020 - 2031
- 8.1 Overview
- 8.2 Cardiomyopathy
- 8.2.1 Global Precision Cardiology Market for Cardiomyopathy (by Technology)
- 8.3 Arrhythmia
- 8.3.1 Global Precision Cardiology Market for Arrhythmia (by Technology)
- 8.4 Aortopathy and Vascular Diseases
- 8.4.1 Global Precision Cardiology Market for Aortopathy and Vascular Diseases (by Technology)
- 8.5 Familial Hypercholesterolemia (FH)
- 8.5.1 Global Precision Cardiology Market for Familial Hypercholesterolemia (FH) (by Technology)
- 8.6 Congenital Heart Defects and Syndromes
- 8.6.1 Global Precision Cardiology Market for Congenital Heart Defects and Syndromes (by Technology)
- 8.7 Other Applications
- 9 Global Precision Cardiology Market, by End User, $Million, 2020-2031
- 9.1 Overview
- 9.2 Hospitals and Diagnostic Laboratories
- 9.3 Academic and Research Institutes
- 9.4 Other End Users
- 10 Global Precision Cardiology Market, by Region, $Million, 2020-2031
- 10.1 Overview
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 U.K.
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Switzerland
- 10.3.7 Rest-of-Europe
- 10.4 Asia-Pacific
- 10.4.1 China
- 10.4.2 India
- 10.4.3 Japan
- 10.4.4 South Korea
- 10.4.5 Australia
- 10.4.6 Rest-of-Asia-Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest-of-Latin America
- 10.6 Rest-of-the-World
- 11 Company Profiles
- 11.1 Overview
- 11.2 Market Value Chain of Precision Cardiology
- 11.3 ARUP Laboratories
- 11.3.1 Company Overview
- 11.3.2 Role of ARUP Laboratories in the Global Precision Cardiology Market
- 11.3.3 Key Customers of the Company
- 11.3.4 Key Competitors of the Company
- 11.3.5 SWOT Analysis
- 11.4 CENTOGENE N.V.
- 11.4.1 Company Overview
- 11.4.2 Role of CENTOGENE N.V. in the Global Precision Cardiology Market
- 11.4.3 Key Customers of the Company
- 11.4.4 Key Competitors of the Company
- 11.4.5 Financials
- 11.4.6 Key Insights About Financial Health of the Company
- 11.4.7 Corporate Strategies
- 11.4.7.1 Synergistic Activities
- 11.4.8 SWOT Analysis
- 11.5 Eurofins Scientific
- 11.5.1 Company Overview
- 11.5.2 Role of Eurofins Scientific in the Global Precision Cardiology Market
- 11.5.3 Key Competitors of the Company
- 11.5.4 Financials
- 11.5.5 SWOT Analysis
- 11.6 Exact Sciences Corporation
- 11.6.1 Company Overview
- 11.6.2 Role of Exact Sciences Corporation in the Global Precision Cardiology Market
- 11.6.3 Key Customers of the Company
- 11.6.4 Key Competitors of the Company
- 11.6.5 Financials
- 11.6.6 Key Insights about Financial Health of the Company
- 11.6.7 Corporate Strategies
- 11.6.7.1 Acquisition
- 11.6.8 SWOT Analysis
- 11.7 Fulgent Genetics, Inc.
- 11.7.1 Company Overview
- 11.7.2 Role of Fulgent Genetics, Inc. in the Global Precision Cardiology Market
- 11.7.3 Key Customers of the Company
- 11.7.4 Key Competitors of the Company
- 11.7.5 Financials
- 11.7.6 Key Insights About Financial Health of the Company
- 11.7.7 Business Strategies
- 11.7.7.1 Service Approval
- 11.7.8 SWOT Analysis
- 11.8 Illumina, Inc.
- 11.8.1 Company Overview
- 11.8.2 Role of Illumina, Inc. in the Global Precision Cardiology Market
- 11.8.3 Key Customers of the Company
- 11.8.4 Key Competitors of the Company
- 11.8.5 Financials
- 11.8.6 Key Insights About Financial Health of the Company
- 11.8.7 SWOT Analysis
- 11.9 Invitae Corporation
- 11.9.1 Company Overview
- 11.9.2 Role of Invitae Corporation in the Global Precision Cardiology Market
- 11.9.3 Key Customers of the Company
- 11.9.4 Key Competitors of the Company
- 11.9.5 Financials
- 11.9.6 Key Insights About Financial Health of the Company
- 11.9.7 Corporate Strategies
- 11.9.7.1 Synergistic Activities
- 11.9.8 SWOT Analysis
- 11.1 Konica Minolta, Inc.
- 11.10.1 Company Overview
- 11.10.2 Role of Konica Minolta, Inc. in the Global Precision Cardiology Market
- 11.10.3 Key Customers of the Company
- 11.10.4 Key Competitors of the Company
- 11.10.5 Financials
- 11.10.6 Key Insights About Financial Health of the Company
- 11.10.7 Corporate Strategies
- 11.10.7.1 Synergistic Activities
- 11.10.8 SWOT Analysis
- 11.11 Laboratory Corporation of America Holdings
- 11.11.1 Company Overview
- 11.11.2 Role of Laboratory Corporation of America Holdings in the Global Precision Cardiology Market
- 11.11.3 Key Customers of the Company
- 11.11.4 Key Competitors of the Company
- 11.11.5 Financials
- 11.11.6 Corporate Strategies
- 11.11.6.1 Synergistic Activities
- 11.11.7 Business Strategies
- 11.11.7.1 Product Launch
- 11.11.8 SWOT Analysis
- 11.12 OPKO Health, Inc.
- 11.12.1 Company Overview
- 11.12.2 Role of OPKO Health, Inc. in the Global Precision Cardiology Market
- 11.12.3 Key Customers of the Company
- 11.12.4 Key Competitors of the Company
- 11.12.5 Financials
- 11.12.2 Key Insights About Financial Health of the Company
- 11.12.3 SWOT Analysis
- 11.13 OraSure Technologies, Inc.
- 11.13.1 Company Overview
- 11.13.2 Role of OraSure Technologies, Inc. in the Global Precision Cardiology Market
- 11.13.3 Key Customers of the Company
- 11.13.4 Financials
- 11.13.5 Key Insights About Financial Health of the Company
- 11.13.6 Business Strategies
- 11.13.6.1 Product Approvals
- 11.13.7 SWOT Analysis
- 11.14 PerkinElmer Inc.
- 11.14.1 Company Overview
- 11.14.2 Role of PerkinElmer Inc. in the Global Precision Cardiology Market
- 11.14.3 Key Customers of the Company
- 11.14.4 Key Competitors of the Company
- 11.14.5 Financials
- 11.14.6 Key Insights About Financial Health of the Company
- 11.14.7 Corporate Strategies
- 11.14.7.1 Business Expansion
- 11.14.8 SWOT Analysis
- 11.15 Quest Diagnostics Incorporated
- 11.15.1 Company Overview
- 11.15.2 Role of Quest Diagnostics Incorporated in the Global Precision Cardiology Market
- 11.15.3 Key Customers of the Company
- 11.15.4 Key Competitors of the Company
- 11.15.5 Financials
- 11.15.6 Business Strategies
- 11.15.6.1 Product Launch
- 11.15.7 SWOT Analysis
- 11.16 Sema4 OpCo, Inc.
- 11.16.1 Company Overview
- 11.16.2 Role of Sema4 OpCo, Inc. in the Global Precision Cardiology Market
- 11.16.3 Key Customers of the Company
- 11.16.4 Key Competitors of the Company
- 11.16.5 Corporate Strategies
- 11.16.5.1 Synergistic Activities
- 11.16.6 SWOT Analysis
- 11.17 Thermo Fisher Scientific Inc.
- 11.17.1 Company Overview
- 11.17.2 Role of Thermo Fisher Scientific Inc. in the Global Precision Cardiology Market
- 11.17.3 Key Customers of the Company
- 11.17.4 Key Competitors of the Company
- 11.17.5 Financials
- 11.17.6 Key Insights About Financial Health of the Company
- 11.17.7 SWOT Analysis
- 11.18 Global Precision Cardiology Market: Emerging Companies
- 11.18.1 GENinCode
- 11.18.1.1 Company Overview
- 11.18.1.2 Role of GENinCode in the Global Precision Cardiology Market
- 11.18.1.3 Key Customers of the Company
- 11.18.1.4 Key Competitors of the Company
- 11.18.1.5 Corporate Strategies
- 11.18.1.5.1 Synergistic Activities
- 11.18.1.6 Business Strategies
- 11.18.1.6.1 Product Approval
- 11.18.1.7 SWOT Analysis
- 11.18.2 Devyser Diagnostics AB
- 11.18.2.1 Company Overview
- 11.18.2.2 Role of Devyser Diagnostics AB in the Global Precision Cardiology Market
- 11.18.2.3 Key Customers of the Company
- 11.18.2.4 Key Competitors of the Company
- 11.18.2.5 Financials
- 11.18.2.6 SWOT Analysis
- List of Figures
- Figure 1: Global Incidence of Cardiovascular Diseases, 2015-2019
- Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Precision Cardiology Market
- Figure 3: Global Precision Cardiology Market (by Offering), $Million, 2020 and 2031
- Figure 4: Global Precision Cardiology Market (by Sample), $Million, 2020 and 2031
- Figure 5: Global Precision Cardiology Market (by Technology), $Million, 2020 and 2031
- Figure 6: Global Precision Cardiology Market (by Application), $Million, 2020 and 2031
- Figure 7: Global Precision Cardiology Market (by End User), $Million, 2020 and 2031
- Figure 8: Global Precision Cardiology Market Snapshot (by Region)
- Figure 9: Global Precision Cardiology Market Segmentation
- Figure 10: Global Precision Cardiology Market: Research Methodology
- Figure 11: Primary Research Methodology
- Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 13: Top-Down Approach (Segment-Wise Analysis)
- Figure 14: Global Precision Cardiology Market, $Million, 2020-2031
- Figure 15: Global Precision Cardiology Market: COVID-19 Impact Analysis
- Figure 16: Share of Key Developments and Strategies, January 2018-January 2022
- Figure 17: Share of Synergistic Activities (by Company), January 2018-January 2022
- Figure 18: Number of Product Launches (by Company), January 2018-January 2022
- Figure 19: Share of Product Approvals (by Company), January 2018-January 2022
- Figure 20: Share of Business Expansion (by Company), January 2018-January 2022
- Figure 21: Market Share Analysis for Global Precision Cardiology Market, $Million, 2019 and 2020
- Figure 22: Growth-Share Analysis for Global Precision Cardiology Market (by Company), 2020
- Figure 23: Growth-Share Analysis for Global Precision Cardiology Market (by Technology), 2020-2031
- Figure 24: Growth-Share Analysis for Global Precision Cardiology Market (by Application), 2020-2031
- Figure 25: FDA Classification and Regulatory Process
- Figure 26: Key Changes in EU IVD Regulation 2017/746
- Figure 27: Europe’s IVD Regulatory Approval Process
- Figure 28: Medical Device Regulatory Approval Process in China
- Figure 29: Medical Device Regulatory Approval Process in South Korea
- Figure 30: Classification of IVD Devices
- Figure 31: Medical Device (IVDs) Regulatory Approval Process in Australia
- Figure 32: Iceberg Analysis of the Global Precision Cardiology Market
- Figure 33: Global Incidence of Cardiovascular Diseases, 2015-2019
- Figure 34: Decreasing Cost and Increasing Output (Terabyte (TB)) of Genome Sequencing, 2009-2025
- Figure 35: Global Precision Cardiology Market (by Offering)
- Figure 36: Global Precision Cardiology Market (by Offering), $Million, 2020 and 2031
- Figure 37: Global Precision Cardiology Market (Service), $Million, 2020-2031
- Figure 38: Global Precision Cardiology Market (Product), $Million, 2020-2031
- Figure 39: Global Precision Cardiology Market (by Sample)
- Figure 40: Global Precision Cardiology Market (by Sample), $Million, 2020 and 2031
- Figure 41: Global Precision Cardiology Market (Blood), $Million, 2020-2031
- Figure 42: Global Precision Cardiology Market (Non-Blood), $Million, 2020-2031
- Figure 43: Global Precision Cardiology Market (by Non-Blood), $Million, 2020 and 2031
- Figure 44: Global Precision Cardiology Market (Saliva), $Million, 2020-2031
- Figure 45: Global Precision Cardiology Market (Buccal Swabs), $Million, 2020-2031
- Figure 46: Global Precision Cardiology Market (Other Non-Blood Samples), $Million, 2020-2031
- Figure 47: Global Precision Cardiology Market (by Technology)
- Figure 48: Global Precision Cardiology Market (by Technology), $Million, 2020 and 2031
- Figure 49: Global Precision Cardiology Market (Sequencing), $Million, 2020-2031
- Figure 50: Global Precision Cardiology Market (by Sequencing), $Million, 2020 and 2031
- Figure 51: Global Precision Cardiology Market (Next-Generation Sequencing (NGS)), $Million, 2020-2031
- Figure 52: Global Precision Cardiology Market (Sanger Sequencing), $Million, 2020-2031
- Figure 53: Global Precision Cardiology Market (Polymerase Chain Reaction (PCR)), $Million, 2020-2031
- Figure 54: Global Precision Cardiology Market (Microarray), $Million, 2020-2031
- Figure 55: Global Precision Cardiology Market (Other Technologies), $Million, 2020-2031
- Figure 56: Global Precision Cardiology Market (by Application)
- Figure 57: Global Precision Cardiology Market (by Application), $Million, 2020-2031
- Figure 58: Global Precision Cardiology Market (Cardiomyopathy), $Million, 2020-2031
- Figure 59: Growth-Share Analysis for Global Precision Cardiology Market for Cardiomyopathy (by Technology), 2020-2031
- Figure 60: Global Precision Cardiology Market (Arrhythmia), $Million, 2020-2031
- Figure 61: Growth-Share Analysis for Global Precision Cardiology Market for Arrhythmia (by Technology), 2020-2031
- Figure 62: Global Precision Cardiology Market (Aortopathy and Vascular Diseases), $Million, 2020-2031
- Figure 63: Growth-Share Analysis for Global Precision Cardiology Market for Aortopathy and Vascular Diseases (by Technology), 2020-2031
- Figure 64: Global Precision Cardiology Market (Familial Hypercholesterolemia (FH)), $Million, 2020-2031
- Figure 65: Growth-Share Analysis for Global Precision Cardiology Market for Familial Hypercholesterolemia (FH) (by Technology), 2020-2031
- Figure 66: Global Precision Cardiology Market (Congenital Heart Defects and Syndromes), $Million, 2020-2031
- Figure 67: Growth-Share Analysis for Global Precision Cardiology Market for Congenital Heart Defects and Syndromes (by Technology), 2020-2031
- Figure 68: Global Precision Cardiology Market (Other Applications), $Million, 2020-2031
- Figure 69: Global Precision Cardiology Market (by End User)
- Figure 70: Global Precision Cardiology Market (by End User), $Million, 2020–2031
- Figure 71: Global Precision Cardiology Market (Hospitals and Diagnostic Laboratories), $Million, 2020-2031
- Figure 72: Global Precision Cardiology Market (Academic and Research Institutes), $Million, 2020-2031
- Figure 73: Global Precision Cardiology Market (Other End Users), $Million, 2020-2031
- Figure 74: Global Precision Cardiology Market Snapshot (by Region)
- Figure 75: Global Precision Cardiology Market (by Region), $Million, 2020-2031
- Figure 76: Global Precision Cardiology Market (by Region), 2020 and 2031
- Figure 77: North America Precision Cardiology Market, $Million, 2020-2031
- Figure 78: North America Precision Cardiology Market (by Country), $Million, 2020-2031
- Figure 79: U.S. Precision Cardiology Market, $Million, 2020-2031
- Figure 80: Canada Precision Cardiology Market, $Million, 2020-2031
- Figure 81: Europe Precision Cardiology Market, $Million, 2020-2031
- Figure 82: Europe Precision Cardiology Market (by Country), $Million, 2020–2031
- Figure 83: Germany Precision Cardiology Market, $Million, 2020-2031
- Figure 84: France Precision Cardiology Market, $Million, 2020-2031
- Figure 85: U.K. Precision Cardiology Market, $Million, 2020-2031
- Figure 86: Italy Precision Cardiology Market, $Million, 2020-2031
- Figure 87: Spain Precision Cardiology Market, $Million, 2020-2031
- Figure 88: Switzerland Precision Cardiology Market, $Million, 2020-2031
- Figure 89: Rest-of-Europe Precision Cardiology Market, $Million, 2020-2031
- Figure 90: Asia-Pacific Precision Cardiology Market, $Million, 2020-2031
- Figure 91: Asia-Pacific Precision Cardiology Market (by Country), $Million, 2020-2031
- Figure 92: China Precision Cardiology Market, $Million, 2020-2031
- Figure 93: India Precision Cardiology Market, $Million, 2020-2031
- Figure 94: Japan Precision Cardiology Market, $Million, 2020-2031
- Figure 95: South Korea Precision Cardiology Market, $Million, 2020-2031
- Figure 96: Australia Precision Cardiology Market, $Million, 2020-2031
- Figure 97: Rest-of-Asia-Pacific Precision Cardiology Market, $Million, 2020-2031
- Figure 98: Latin America Precision Cardiology Market, $Million, 2020-2031
- Figure 99: Latin America Precision Cardiology Market (by Country), $Million, 2020-2031
- Figure 100: Brazil Precision Cardiology Market, $Million, 2020-2031
- Figure 101: Mexico Precision Cardiology Market, $Million, 2020-2031
- Figure 102: Rest-of-Latin America Precision Cardiology Market, $Million, 2020-2031
- Figure 103: Rest-of-the-World Precision Cardiology Market, $Million, 2020-2031
- Figure 104: Total Number of Companies Profiled
- Figure 105: Global Precision Cardiology Market: Value Chain
- Figure 106: ARUP Laboratories: Service Portfolio
- Figure 107: ARUP Laboratories: SWOT Analysis
- Figure 108: CENTOGENE N.V.: Service Portfolio
- Figure 109: CENTOGENE N.V.: Overall Financials, $Million, 2018-2020
- Figure 110: CENTOGENE N.V.: Revenue (by Business Segment), $Million, 2018–2020
- Figure 111: CENTOGENE N.V.: Revenue (by Region), $Million, 2018-2020
- Figure 112: CENTOGENE N.V.: R&D Expenditure, $Million, 2018-2020
- Figure 113: CENTOGENE N.V.: SWOT Analysis
- Figure 114: Eurofins Scientific: Service Portfolio
- Figure 115: Eurofins Scientific: Overall Financials, $Million, 2018-2020
- Figure 116: Eurofins Scientific: Revenue (by Region), $Million, 2018-2020
- Figure 117: Eurofins Scientific: SWOT Analysis
- Figure 118: Exact Sciences Corporation: Service Portfolio
- Figure 119: Exact Sciences Corporation: Overall Financials, $Million, 2018-2020
- Figure 120: Exact Sciences Corporation: Revenue (by Business Segment), $Million, 2018-2020
- Figure 121: Exact Sciences Corporation: Revenue (by Region), $Million, 2018-2020
- Figure 122: Exact Sciences Corporation: R&D Expenditure, $Million, 2018-2020
- Figure 123: Exact Sciences Corporation: SWOT Analysis
- Figure 124: Fulgent Genetics, Inc.: Service Portfolio
- Figure 125: Fulgent Genetics, Inc.: Overall Financials, $Million, 2018-2020
- Figure 126: Fulgent Genetics, Inc.: Revenue (by Region), $Million, 2018-2020
- Figure 127: Fulgent Genetics, Inc.: R&D Expenditure, $Million, 2018-2020
- Figure 128: Fulgent Genetics, Inc.: SWOT Analysis
- Figure 129: Illumina, Inc.: Product Portfolio
- Figure 130: Illumina, Inc.: Overall Financials, $Million, 2018-2020
- Figure 131: Illumina, Inc.: Revenue (by Business Segment), $Million, 2018–2020
- Figure 132: Illumina, Inc.: Revenue (by Region), $Million, 2018–2020
- Figure 133: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020
- Figure 134: Illumina, Inc.: SWOT Analysis
- Figure 135: Invitae Corporation: Service Portfolio
- Figure 136: Invitae Corporation: Overall Financials, $Million, 2018-2020
- Figure 137: Invitae Corporation: Revenue (by Business Segment), $Million, 2018–2020
- Figure 138: Invitae Corporation: Revenue (by Region), $Million, 2018-2020
- Figure 139: Invitae Corporation: R&D Expenditure, $Million, 2018-2020
- Figure 140: Invitae Corporation: SWOT Analysis
- Figure 141: Konica Minolta, Inc.: Service Portfolio
- Figure 142: Konica Minolta, Inc.: Overall Financials, $Million, 2018-2020
- Figure 143: Konica Minolta, Inc.: Revenue (by Business Segment), $Million, 2019–2020
- Figure 144: Konica Minolta, Inc.: Revenue (by Healthcare Business), $Million, 2019–2020
- Figure 145: Konica Minolta, Inc.: Revenue (by Region), $Million, 2018-2020
- Figure 146: Konica Minolta, Inc.: R&D Expenditure, $Million, 2018-2020
- Figure 147: Konica Minolta, Inc.: SWOT Analysis
- Figure 148: Laboratory Corporation of America Holdings: Service Portfolio
- Figure 149: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2018-2020
- Figure 150: Laboratory Corporation of America Holdings: Revenue (by Business Segment), $Million, 2018-2020
- Figure 151: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2018-2020
- Figure 152: Laboratory Corporation of America Holdings: SWOT Analysis
- Figure 153: OPKO Health, Inc.: Service Portfolio
- Figure 154: OPKO Health, Inc.: Overall Financials, $Million, 2018-2020
- Figure 155: OPKO Health, Inc.: Revenue (by Business Segment), $Million, 2018–2020
- Figure 156: OPKO Health, Inc.: Revenue (by Region), $Million, 2018-2020
- Figure 157: OPKO Health, Inc.: R&D Expenditure, $Million, 2018-2020
- Figure 158: OPKO Health: SWOT Analysis
- Figure 159: OraSure Technologies, Inc.: Product Portfolio
- Figure 160: OraSure Technologies, Inc.: Overall Financials, $Million, 2018-2020
- Figure 161: OraSure Technologies, Inc.: Revenue (by Business Segment), $Million, 2018-2020
- Figure 162: OraSure Technologies, Inc.: Revenue (by Molecular Solutions), $Million, 2019-2020
- Figure 163: OraSure Technologies, Inc.: Revenue (by Region), $Million, 2018-2020
- Figure 164: OraSure Technologies, Inc.: R&D Expenditure, $Million, 2018-2020
- Figure 165: OraSure Technologies, Inc.: SWOT Analysis
- Figure 166: PerkinElmer Inc.: Service and Product Portfolio
- Figure 167: PerkinElmer Inc.: Overall Financials, $Million, 2018-2020
- Figure 168: PerkinElmer Inc.: Revenue (by Business Segment), $Million, 2018-2020
- Figure 169: PerkinElmer Inc.: Revenue (by Region), $Million, 2018-2020
- Figure 170: PerkinElmer Inc.: R&D Expenditure, $Million, 2018-2020
- Figure 171: PerkinElmer Inc.: SWOT Analysis
- Figure 172: Quest Diagnostics Incorporated: Service Portfolio
- Figure 173: Quest Diagnostics Incorporated: Overall Financials, $Million, 2018-2020
- Figure 174: Quest Diagnostics Incorporated: Revenue (by Business Segment), $Million, 2018-2020
- Figure 175: Quest Diagnostics Incorporated: SWOT Analysis
- Figure 176: Sema4 OpCo, Inc.: Service Portfolio
- Figure 177: Sema4 OpCo, Inc.: SWOT Analysis
- Figure 178: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 179: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020
- Figure 180: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2018–2020
- Figure 181: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018–2020
- Figure 182: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
- Figure 183: Thermo Fisher Scientific Inc.: SWOT Analysis
- Figure 184: GENinCode: Product Portfolio
- Figure 185: GENinCode: SWOT Analysis
- Figure 186: Devyser Diagnostics AB: Product Portfolio
- Figure 187: Devyser Diagnostics AB: Overall Financials, $Million, 2018-2020
- Figure 188: Devyser Diagnostics AB: SWOT Analysis
- List of Tables
- Table 1: Likert Scale
- Table 2: Impact Analysis of Market Drivers
- Table 3: Impact Analysis of Market Restraints
- Table 4: Precision Cardiology Services Offered by Key Players
- Table 5: Precision Cardiology Products Offered by Key Manufacturers
- Table 6: Precision Cardiology Tests for Cardiomyopathy
- Table 7: Precision Cardiology Tests for Arrhythmia
- Table 8: Precision Cardiology Tests for Aortopathy and Vascular Diseases
- Table 9: Precision Cardiology Tests for Familial Hypercholesterolemia (FH)
- Table 10: Precision Cardiology Tests for Congenital Heart Defects and Syndromes
- Table 11: Precision Cardiology Tests for Other Applications
- Table 12: North America: Market Dynamics
- Table 13: Europe: Market Dynamics
- Table 14: Asia-Pacific: Market Dynamics
- Table 15: Latin America: Market Dynamics
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.